Viatris Inc (VTRS)

Industry Drug Manufacturers - Specialty & Generic


This stock can be held in an Investment ISA and an Investment Account
Sell

$9.00

Buy

$9.03

arrow-down$-0.26 (-2.81%)

Prices updated at 13 Mar 2025, 13:25 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories.

Most recent dividend payment

0.120
Cash Dividend
10 Mar 2025
27 Feb 2025
10 Mar 2025
18 Mar 2025

Total dividend yield

Created with Highcharts 7.2.2Total yield (%)Total yield (%)2021202220232024202502.557.510

Dividend history and forecast data table

YearDividend per shareDividend growth (%)
20250.1200-
20240.4800-
20230.4800-
20220.48000.45
20210.3300-
2020--
2019--
2018--
2017--
2016--

Total dividend yield data table

Dividend yield (%)Buyback yield (%)
20255.202.25
20243.861.67
20234.431.90
20224.31-
20212.44-
2020--
2019--
2018-6.60
2017--
2016--

Dividend per share

Created with Highcharts 7.2.2Dividend per shareDividend per share2021202220232024202500.20.40.6

% of earnings paid to shareholders

Created with Highcharts 7.2.2Payout ratio (%)Payout ratio (%)20212022202320242025020406080

Dividend per share data table

YearDividend per share
20250.1200
20240.4800
20230.4800
20220.4800
20210.3300
2020-
2019-
2018-
2017-
2016-

% of earnings paid to shareholders data table

YearPayout ratio (%)
2025-
2024-
202331.79
202271.21
2021-
2020-
2019-
2018-
2017-
2016-
Latest Financial Report as of 13 Mar 2025
Dividend amount and dividend per share are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.